TGFB1 and melanoma: Our results suggest that identification and modulation of an immunosuppressive cytokine milieu, for example, high plasma levels of TGF-β might allow for restoration of endogenous antitumor immunity, including recovery of NK cytolytic function, and ultimately improve outcomes of melanoma therapy.